{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:44:01Z","timestamp":1758991441784,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["14\/23\/18"],"award-info":[{"award-number":["14\/23\/18"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The KERALINK trial tests the hypothesis that corneal cross-linking (CXL) treatment reduces the progression of keratoconus in comparison to standard care in patients aged 10\u201316\u2009years. This article describes the statistical analysis plan for this trial as an update to the published protocol. It is written before the end of the patient follow-up, while the outcome of the trial is still unknown.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Design and methods<\/jats:title>\n<jats:p>KERALINK is a randomised controlled, observer-masked, multicentre trial in progressive keratoconus comparing epithelium-off CXL with standard care, including spectacles or contact lenses as necessary for best-corrected acuity. Keratoconus is a disorder of the shape of the cornea in which the normally round dome-shaped clear front window of the eye (cornea) thins progressively leading to a cone-like bulge. This impairs the ability of the eye to focus properly, causing reduced vision which requires spectacle or contact lens wear or, in a minority of patients, eventually corneal replacement by a transplant for best vision. The primary outcome measure is the between-group difference in K<jats:sub>2<\/jats:sub> at 18\u2009months adjusted for K<jats:sub>2<\/jats:sub> at baseline examination. K<jats:sub>2<\/jats:sub> is the value of the steepest corneal meridian as measured on Pentacam topography. Secondary outcomes are keratoconus progression, time to keratoconus progression, visual acuity, refraction, apical corneal thickness and adverse events. Patient-reported effects will be explored by questionnaires. We describe in detail the statistical aspects of KERALINK: the outcome measures, the sample size calculation, general analysis principles, the planned descriptive statistics and statistical models, and planned subgroup and sensitivity analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The KERALINK statistical analysis will provide comprehensive and precise information on the relative effectiveness of the two treatments. The plan will be implemented in May 2020 when follow-up for the trial is completed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>EudraCT, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-001460-11\">2016-001460-11<\/jats:ext-link>. Registered on 19 May 2016.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-020-04392-1","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:03:45Z","timestamp":1591956225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Corneal cross-linking versus standard care in children with keratoconus \u2013 a randomised, multicentre, observer-masked trial of efficacy and safety (KERALINK): a statistical analysis plan"],"prefix":"10.1186","volume":"21","author":[{"given":"Kashfia","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline J.","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F. P.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"4392_CR1","doi-asserted-by":"publisher","first-page":"e028761","DOI":"10.1136\/bmjopen-2018-028761","volume":"9","author":"K Chowdhury","year":"2019","unstructured":"Chowdhury K, Dore C, Burr JM, et al. A randomised, controlled, observer-masked trial of corneal cross-linking for progressive keratoconus in children: the KERALINK protocol. BMJ Open. 2019;9:e028761. https:\/\/doi.org\/10.1136\/bmjopen-2018-028761.","journal-title":"BMJ Open"},{"issue":"12","key":"4392_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/S0886-3350(02)01639-5","volume":"28","author":"SB Kaye","year":"2002","unstructured":"Kaye SB, Harris WF. Analyzing refractive data. J Cataract Refract Surg. 2002;28(12):2109\u201316.","journal-title":"J Cataract Refract Surg"},{"key":"4392_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11136-011-9971-y","volume":"21","author":"J Ratcliffe","year":"2012","unstructured":"Ratcliffe J, Stevens K, Flynn T, Brazier J, Sawyer M. An assessment of the construct validity of the CHU9D in the Australian adolescent general population. Qual Life Res. 2012;21:717\u201325.","journal-title":"Qual Life Res"},{"key":"4392_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1049732309358328","volume":"20","author":"K Stevens","year":"2010","unstructured":"Stevens K. Working with children to develop dimensions for a preference-based, generic, pediatric health-related quality-of-life measure. Qual Health Res. 2010;20:340\u201351.","journal-title":"Qual Health Res"},{"issue":"8","key":"4392_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s11136-009-9524-9","volume":"18","author":"K Stevens","year":"2009","unstructured":"Stevens K. Developing a descriptive system for a new preference-based measure of health-related quality of life for children. Qual Life Res. 2009;18(8):1105\u201313.","journal-title":"Qual Life Res"},{"key":"4392_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hec.3165","volume":"25","author":"J Ratcliffe","year":"2016","unstructured":"Ratcliffe J, Huynh E, Stevens K, Brazier J, Sawyer M, Flynn T. Nothing about us without us? A comparison of adolescent and adult health-state values for the child health utility-9D using profile case best-worst scaling. Health Econ. 2016;25:486\u201396.","journal-title":"Health Econ"},{"issue":"8","key":"4392_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","volume":"30","author":"K Stevens","year":"2012","unstructured":"Stevens K. Valuation of the Child Health Utility 9D Index. Pharmacoeconomics. 2012;30(8):729\u201347.","journal-title":"Pharmacoeconomics"},{"key":"4392_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/bjo.2009.171181","volume":"94","author":"J Khadka","year":"2010","unstructured":"Khadka J, Ryan B, Margrain TH, Court H, Woodhouse JM. Development of the 25-item Cardiff Visual Ability Questionnaire for Children (CVAQC). Br J Ophthalmol. 2010;94:730\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4392_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ophtha.2013.10.028","volume":"121","author":"C Wittig-Silva","year":"2014","unstructured":"Wittig-Silva C, Chan E, Islam FM, Wu T, Whiting M, Snibson GR. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. Ophthalmology. 2014;121:812\u201321.","journal-title":"Ophthalmology"},{"key":"4392_CR10","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Statistical Principles for Clinical Trials E9. 1998. https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3973-4."},{"issue":"4","key":"4392_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1740774512450098","volume":"9","author":"IR White","year":"2012","unstructured":"White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clin Trials. 2012;9(4):396\u2013407.","journal-title":"Clin Trials"},{"key":"4392_CR12","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Structure and content of clinical study reports E3. 1995."},{"key":"4392_CR13","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04392-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T23:33:20Z","timestamp":1623454400000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4392"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04392-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study has been approved and is overseen by the National Research Ethics Service Committee (London - Brent Research Ethics Committee, 16\/LO\/0913, 30 June 2016). We have obtained informed consent from all participants in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"523"}}